Please check your internet connection and try again.
# Tabovoihep
## Overview
Tabovoihep is a brand name for **Tafenoquine**, an antimalarial drug. It is an 8-aminoquinoline derivative.
## Primary Indications
* **Malaria Prophylaxis:** Prevention of malaria in individuals 18 years of age and older traveling to or residing in malaria-endemic areas.
* **Radical Cure of *Plasmodium vivax* Malaria:** Elimination of *Plasmodium vivax* hypnozoites in the liver to prevent relapse.
## Adult Dosing
* **Malaria Prophylaxis:**
* **For travel:** A single dose of 200 mg taken 1 week before, 200 mg taken 1 day before, 200 mg taken 7 days after departure, and 200 mg taken 4 weeks after departure.
* **During residence:** A single dose of 200 mg taken 1 day before, 200 mg taken 7 days after departure, and 200 mg taken 4 weeks after departure.
* **Radical Cure of *P. vivax* Malaria:**
* A single dose of 200 mg followed by a single dose of 100 mg taken 24 hours later.
## Pediatric Dosing
Tafenoquine is **not recommended** for children under 18 years of age due to insufficient data.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is typically needed in mild to moderate renal impairment. Caution is advised in severe renal impairment.
* **Hepatic Impairment:** No dose adjustment is typically needed in mild to moderate hepatic impairment. Caution is advised in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to tafenoquine or other 8-aminoquinolines.
* Individuals with Glucose-6-phosphate dehydrogenase (G6PD) deficiency. Screening for G6PD deficiency is mandatory before initiating treatment.
* Individuals with a history of certain psychiatric disorders (e.g., psychosis) may be at increased risk.
## Adverse Effects
* **Common:** Headache, nausea, vomiting, diarrhea, dizziness, insomnia, abdominal pain, rash.
* **Serious:** Hemolytic anemia (especially in G6PD deficient individuals), methemoglobinemia, psychiatric disturbances (anxiety, depression, hallucinations), cardiac arrhythmias (QT prolongation), ocular toxicity (corneal deposits).
## Key Drug Interactions
* **CYP1A2 Inhibitors (e.g., fluvoxamine, ciprofloxacin):** May increase tafenoquine concentrations.
* **CYP1A2 Inducers (e.g., carbamazepine, rifampin):** May decrease tafenoquine concentrations.
* **Drugs that prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics):** Increased risk of cardiac arrhythmias.
* **Mefloquine:** Co-administration is not recommended due to increased risk of CNS and cardiac events.
## Monitoring
* **G6PD Deficiency Screening:** Mandatory before initiating therapy.
* **Hemoglobin and Hematocrit:** Monitor for signs of hemolysis.
* **Renal and Hepatic Function:** Baseline and periodically as clinically indicated.
* **Mental Status:** Assess for psychiatric adverse effects.
* **ECG:** Consider baseline and follow-up ECGs, especially in patients with risk factors for QT prolongation.
## Clinical Pearls
* Tafenoquine is a single-dose radical cure for *P. vivax* malaria, simplifying treatment regimens compared to older drugs.
* For malaria prophylaxis, it requires a loading dose before travel and is taken weekly or monthly depending on the regimen.
* **Crucially, G6PD deficiency must be ruled out before administration due to the significant risk of severe hemolytic anemia.**
* Patients should be advised to report any new or worsening psychiatric symptoms, visual changes, or signs of unusual fatigue or dark urine.
***
*This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and local protocols for definitive patient management decisions.*
